Erasca, Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

Erasca, Inc. has submitted its Q1 2024 10-Q filing, detailing financial performance and business activities.

AI Summary

Erasca, Inc. (ERAS) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Erasca, Inc. filed a 10-Q report for the period ending March 31, 2024. The filing includes financial data and business updates for the first quarter of 2024. Key entities mentioned include Katmai Pharmaceuticals, Inc., NiKang Therapeutics, Inc., and Novartis Pharma AG. The company is involved in various license agreements and equity incentive plans. Financial instruments such as US Treasury Securities and Corporate Debt Securities are noted.

Why It Matters

For investors and stakeholders tracking Erasca, Inc., this filing contains several important signals. This 10-Q provides investors with the latest financial health and operational status of Erasca, Inc. as of Q1 2024. Understanding the details within this filing is crucial for assessing the company's progress in its drug development and licensing activities.

Risk Assessment

Risk Level: medium — Erasca, Inc. shows moderate risk based on this filing. The company is in the pharmaceutical development stage, which inherently carries high risks related to clinical trials, regulatory approvals, and market adoption, as indicated by the nature of its business and licensing agreements.

Analyst Insight

Monitor Erasca's progress in its ongoing clinical trials and partnership developments as detailed in this 10-Q to gauge future revenue potential and R&D success.

Key Numbers

• 2024-03-31 — Reporting Period End Date (10-Q filing)
• 2023-03-31 — Comparative Period End Date (Research and Development Expense comparison)
• 2020-03-01 — Agreement Start Date (License Agreement with Katmai Pharmaceuticals, Inc.)
• 2020-02-01 — Agreement Start Date (License Agreement with NiKang Therapeutics, Inc.)

Key Players & Entities

• Erasca, Inc. (company) — Filer of the 10-Q report
• Katmai Pharmaceuticals, Inc. (company) — Mentioned in relation to license agreements and preferred stock
• NiKang Therapeutics, Inc. (company) — Mentioned in relation to a license agreement
• Novartis Pharma AG (company) — Mentioned in relation to license agreements
• LifeArc (company) — Mentioned in relation to a license agreement
• AffiniT Therapeutics Inc (company) — Mentioned in relation to financial reporting
• 2024-03-31 (date) — End of the reporting period
• 2023-03-31 (date) — Comparative period for R&D expenses

FAQ

Risk Factors

• Regulatory Risks [high — regulatory]: The company's drug development is subject to extensive government regulation, including clinical trials and approval processes, which can be lengthy and costly.
• Funding and Liquidity [high — financial]: As a development-stage company, Erasca relies on external financing and may face challenges in securing sufficient capital to fund its operations and research.
• Research and Development Failures [high — operational]: The success of Erasca's business depends on the successful development of its product candidates, which may fail in clinical trials or prove not to be commercially viable.
• Competition [medium — market]: The pharmaceutical market is highly competitive, with many companies developing similar therapies, which could impact Erasca's market share and profitability.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q filing.

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ERAS Nasdaq Glo

Filing Documents

• eras-20240331.htm (10-Q) — 1542KB
• eras-ex31_1.htm (EX-31.1) — 14KB
• eras-ex31_2.htm (EX-31.2) — 14KB
• eras-ex32_1.htm (EX-32.1) — 8KB
• eras-ex32_2.htm (EX-32.2) — 8KB
• img199610639_0.jpg (GRAPHIC) — 214KB
• 0000950170-24-055668.txt ( ) — 8254KB
• eras-20240331.xsd (EX-101.SCH) — 1103KB
• eras-20240331_htm.xml (XML) — 1546KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024 and 2023 2 Condensed Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2024 and 2023 3 Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 4 Notes to Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 31 Item 3. Defaults Upon Senior Securities 31 Item 4. Mine Safety Disclosures 31 Item 5. Other Information 31 Item 6. Exhibits 32

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

. Financial Statements

Item 1 . Financial Statements. Erasca, Inc. Condensed Consolidated Balance Sheets (In thousands, except share and par value amounts) (Unaudited) March 31, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 76,726 $ 93,075 Short-term marketable securities 220,959 219,275 Prepaid expenses and other current assets 8,938 8,326 Total current assets 306,623 320,676 Long-term marketable securities — 9,642 Property and equipment, net 21,358 22,327 Operating lease assets 37,177 37,861 Restricted cash 408 408 Other assets 4,456 4,383 Total assets $ 370,022 $ 395,297 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 2,633 $ 2,000 Accrued expenses and other current liabilities 16,577 20,186 Proceeds from prepayment of private placement 6,907 — Operating lease liabilities 4,126 3,970 Total current liabilities 30,243 26,156 Operating lease liabilities, net of current portion 50,811 51,889 Other liabilities 559 566 Total liabilities 81,613 78,611 Commitments and contingencies (Note 11) Stockholders' equity: Preferred stock, $ 0.0001 par value; 80,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023 — — Common stock, $ 0.0001 par value; 800,000,000 shares authorized at March 31, 2024 and December 31, 2023; 151,497,138 and 151,462,103 shares issued at March 31, 2024 and December 31, 2023, respectively; 151,249,219 and 151,090,227 shares outstanding at March 31, 2024 and December 31, 2023, respectively 15 15 Additional paid-in capital 929,634 922,607 Accumulated other comprehensive (loss) income ( 210 ) 77 Accumulated deficit ( 641,030 ) ( 606,013 ) Total stockholders' equity 288,409 316,686 Total liabilities and stockholders' equity $ 370,022 $ 395,297

View Full Filing

View this 10-Q filing on SEC EDGAR